We aimed to estimate the RSV burden and impact of adjuvanted RSV prefusion F protein vaccine (RSVPreF3) vaccination in OA in 6 countries; Argentina, Brazil, Chile, Colombia, Mexico, Panama.Methods: A static multi-cohort Markov model was used to estimate RSV-related outcomes over a 3-year ...
表2.RSV-A和RSV-B中和滴度和RSVPreF3结合的免疫球蛋白浓度:按体液免疫原性方案设定 缩写:ED60,估计稀释度60;EU,酶联免疫吸附测定单位;GMC,几何平均浓度;GMT,几何平均中和滴度;IgG,免疫球蛋白G;MGI,给定时间点(第1天)的平均几何增长;RSV,呼吸道合胞病毒;RSVPreF3,RSV预融合F蛋白。 a GMT(95%CI),ED60;b...
adjuvanted RSVPreF3 vaccinecost-effectivenessolder adultsvaccinationRespiratory syncytial virus (RSV) is a common cause of acute respiratory illness in individuals of all ages, with adults aged≥60years and adults with certain chronic conditions at increased risk of severe RSV-related outcomes. This ...
Administered by intramuscular injection, the RSVPreF3OA vaccine formulation contains the highly conserved RSV fusion protein, stabilised in its trimeric prefusion conformation, adjuvanted with AS01E. As demonstrated in the pivotal, randomised, placebo-controlled, multinational, phase3 AReSVi-006 trial, ...
Following favorable safety evaluation, a staggered enrolment with 2 steps followed in OA aged 60–80 years, who were randomized 1:1:1:1:1:1:1:1:1:1 to receive 1 of the 9 RSV vaccine formulations containing Low-, Medium- or High-dose of RSVPreF3 non-adjuvanted or adjuvanted with A...